Tirzepatide (compound version Mounjaro) is a once weeklyinjectable medication that works by mimicking the action of a hormone called GLP-1 (glucagon-like peptide-1) GLP-1 is released naturally by the gut and stimulates insulin release, lower blood sugar levels and reduce appetite. By activating the GLP-1 receptor, tirzepatide helps to regulate blood sugar levels and decrease the feeling of hunger, ultimately leading to weight loss. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity.
Tirzepatide (Mounjaro)
Tirzepatide is available in three different doses:2.5, 5mg, 7.5mg, 10mg, The typical starting dose is 2.5 mg once weekly for four weeks, followed by an increase to 5mg once weekly. If further weight loss is desired, the dose can be increased to 10mg once weekly. Tirzepatide micics the GLP-1 hormone and the GIP hormone. The GIP hormone can also trigger insulin creation and sensations of fullness. This means tirzepatide may offer an extra weight loss boost. Tirzepatide is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm.
Dose
Units
Frequency
2.5mg
25 units
Once weekly
5 mg
50 units
Once weekly
7.5 mg
75 units
Once weekly
10 mg
100 weekly
Once weekly
){kind=link}